Revolutionary impact of nanodrug delivery on neuroscience

Current Neuropharmacology

Volumn 10, Issue 4, 2012, Pages 370-392

  Khanbabaie, Reza ^a,b   Jahanshahi, Mohsen ^a  

^a BABOL NOSHIRVANI UNIVERSITY OF TECHNOLOGY   (Iran)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Nano nervous drugs; Nanodrug; Nanofabrication and purification; Nervous system; Neuroscience

Indexed keywords

2 METHOXYESTRADIOL; AEROLEF; ALPHA LACTALBUMIN; CAMPTOTHECIN; CARBON NANOTUBE; CYCLOSPORIN A; DENDRIMER; DOXORUBICIN; FENTANYL; GELATIN; IDARUBICIN; INORGANIC COMPOUND; ION CHANNEL; LIPOSOME; NANOCRYSTAL; NANODRUG; NANOPARTICLE; NEUROHORMONE; NEUROTRANSMITTER; PANZEM NCD; PROTHECAN; SOLID LIPID NANOPARTICLE; TOBRAMYCIN; UNCLASSIFIED DRUG; VINCRISTINE; VINCRISTINE SULFATE; VIVAGEL;

ADDICTION; ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; COACERVATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; EMULSION; GELATION; HUMAN; NANOTECHNOLOGY; NEUROPHARMACOLOGY; NEUROSCIENCE; NONHUMAN; PARKINSON DISEASE; PARTICLE SIZE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PURIFICATION; REVIEW; SPRAY DRYING; SURFACE CHARGE;

EID: 84874913080     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/157015912804499456     Document Type: Review

References (245)

1. Engelhardt, B. and Sorokin, L. The blood-brain and the bloodcerebrospinal fluid barriers: function and dysfunction. Semin. Immunopathol., 2009, 31, 497-511.
2. Reese, T. and Karnovsky, M. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J. Cell Biol., 1967, 34, 207-217.
3. Rao, V. V., Dahlheimer, J. L., Bardgett, M. E., Snyder, A. Z., Finch, R. A., Sartorelli, A. C. and Piwnica-Worms, D. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the bloodcerebrospinal-fluid drug-permeability barrier. Proc. Natl. Acad. Sci. U.S.A., 1999, 96, 3900-3905.
4. Lo, E. H., Singhal, A. B., Torchilin, V. P. and N.J., A. Drug delivery to damaged brain. Brain Res. Rev., 2001, 38, 140-148.
5. Witt, K. A., Gillespie, T. J., Huber, J. D., Egleton, R. D. and Davis, T. P. Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability. Peptides, 2001, 22, 2329-2343.
6. Siegal, T. and zylber-Katz, E. Strategies for increasing drug delivery to the brain: focus on brain lymphoma. Clin. Pharmacokinet., 2002, 41, 171-186.
7. Misra, A., S., G., Shahiwala, A. and Shah, S. P. Drug delivery to the central nervous system: a review. J. Pharm. Pharmaceut. Sci., 2003, 6, 252-273.
8. Rodrigues, A. and Emeje, M. Recent applications of starch derivatives in nanodrug delivery. Carbohydrate Polymers, 2012, 87, 987-994.
9. Feynman, R. There's plenty of room at the bottom. Eng. Sci., 1960, 23, 22-36.
10. Silva, G. A. Introduction to Nanotechnology and Its Applications to Medicine. Surg. Neurol., 2004, 61, 216-220.
11. Tokumasu, F., Jin, A. J., Feigenson, G. W. and Dvorak, J. A. Atomic force microscopy of nanometric liposome adsorption and nanoscopic membrane domain formation. Ultramicroscopy, 2003, 97, 217-227.
12. Shaji, J. and Patole, V. Protein and Peptide Drug Delivery: Oral Approaches. Indian J. Pharm. Sci., 2008, 70, 269-277.
13. Liu, Y., Sun, C., Hao, Y., Jiang, T., Zheng, L. and Wang, S. Mechanism of Dissolution Enhancement and Bioavailability of Poorly Water Soluble Celecoxib by Preparing Stable Amorphous Nanoparticles. J. Pharm. Pharm. Sci., 2010, 13, 589-606.
14. Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W. and Kopple, K. D. Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. J. Med. Chem., 2002, 45, 2615-2623.
15. Ignatova, Z. Monitoring protein stability in vivo. Microb Cell Fact., 2005, 4, 23.
16. Lalatsa, A., Schätzlein, A. and Uchegbu, I. Drug Deliv. Across the Blood-Brain Barrier. University of London, London, 2011.
17. Hamman, J. H., Enslin, G. M. and Kotzé, A. Oral Delivery of Peptide Drugs: Barriers and Developments. BioDrugs, 19, 2005, 165-177.
18. Win, K. Y. and Feng, S.-S. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials, 26, 2005, 2713-2722.
19. Jain, S., Tiwary, A. and Jain, N. Sustained and targeted delivery of an anti-HIV agent using elastic liposomal formulation: mechanism of action. Curr. Drug Deliv., 2006, 3, 157-166.
20. Utreja, P., Jain, S. and Tiwary, A. Novel drug delivery systems for sustained and targeted delivery of anti-cancer drugs: current status and future prospects. Curr. Drug Deliv., 2010, 7, 152-161.
21. Yun, Y., Goetz, D., Yellen, P. and Chen, W. Hyaluronan microspheres for sustained gene delivery and site-specific targeting. Biomaterials, 2004, 25, 147-157.
22. Labiris, N. R. and Dolovich, M. B. Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol., 2003, 56, 600-612.
23. Modeste, G. F., Sahidou, S., Patrick, E. A., Anges, Y. W., Yélignan, H. A. S., Martin, A. and Michel, B. Therapeutic effectiveness of coartem® in simple malaria treatment among children less than age of 5 yeasrs in the comune of aguegues in benin. Continental J. Pharm. Sci., 2012, 6, 1.
24. Manish, G. and Vimukta, S. Targeted drug delivery system: A Review. Res. J. Chem. Sci., 2011, 1, 135-138.
25. Piafsky, K. Disease-induced changes in the plasma binding of basic drugs. Clin. Pharmacokinetics, 1980, 5, 246-262.
26. Dave, B. S., Amin, A. F. and Patel, M. M. Gastroretentive Drug Delivery System of Ranitidine Hydrochloride: Formulation and In Vitro Evaluation. AAPS Pharm. Sci. Tech., 2004, 5, 2.
27. Gilmore, J. L., Yi, X., Quan, L. and Kabanov, A. V. Novel Nanomaterials for Clinical Neuroscience. J. Neuroimmune Pharmacol., 2008, 3, 83-94.
28. Jahanshahi, M., Shariaty-Niassar, M., Rostami, A. A., Molavi, H. and Toubi, F. Arc-discharge Carbon Nanotube Fabrication in Solution:Electrochemistry and Voltametric Tests. Aust. J. Basic App. Sci., 4, 12, 2010, 5915-5922.
29. Jabari Seresht, R., Jahanshahi, M. and Toubi, F. Applying the Multiple Linear Regressions and Taguchi Design Method for Controlled Fabrication of Carbon Nanotubes in Solution. Fullerenes, Nanotubes, and Carbon Nanostructures, 2010, 18, 148-159.
30. Greiner, A., Wendorff, J., Yarin, A. and Zussman, E. Biohybrid nanosystems with polymer nanofibers and nanotubes. Appl. Microbiol. Biotechnol., 2006, 71, 387-393.
31. Hartgerink, J., Granja, J., Milligan, R. and Ghadiri, M. Selfassembling peptide nanotubes. J. Am. Chem. Soc., 1996, 118, 43-50.
32. Tsai, C., Zheng, J., Aleman, C. and Nussinov, R. Structure by design: from single proteins and their building blocks to nanostructures. Trends Biotechnol., 24, 2006, 449-454.
33. Iijima, S. Helical microtubules of graphitic carbon. Nature, 354, 1991, 56-58.
34. Baxendale, M. Biomolecular applications of carbon nanotubes. IEE. Proc. Nanobiotechnol., 2003, 150, 3-8.
35. Fereidoon, A., Ghorbanzadeh Ahangari, M., Ganji, M. D. and Jahanshahi, M. Density functional theory investigation of the mechanical properties of single-walled carbon nanotubes. Comput. Mater. Sci., 2012, 53, 377-381.
36. Lovat, V., Pantarotto, D., Lagostena, L., Cacciari, B., Grandolfo, M., Righi, M., Spalluto, G., Prato, M. and Ballerini, L. Carbon nanotube substrates boost neuronal electrical signaling. Nano Letter, 2005, 5, 1107-1111.
37. Matsumoto, K., Sato, C., Naka, Y., Kitazawa, A., Whitby, R. L. D. and Shimizu, N. Neurite Outgrowths of Neurons with Neurotrophin-Coated Carbon Nanotubes. J. Biosci. Bioeng., 2007, 103, 3.
38. Wu, D., Pak, E. S., Wingard, C. J. and Murashov, A. K. Multiwalled carbon nanotubes inhibit regenerative axon growth of dorsal root ganglia neurons of mice. Neurosci. Lett., 2012, 507, 72-77.
39. Matsumoto, K., Sato, C., Naka, Y., Kitazawa, A., Whitby, R. and Shimizu, N. Neurite outgrowths of neurons with neurotrophincoated carbon nanotubes. J. Biosci. Bioeng., 2007, 103, 216-220.
40. Razavi-Nouri, M., Ghorbanzadeh-Ahangari, M., Fereidoon, A. and Jahanshahi, M. Effect of carbon nanotubes content on crystallization kinetics and morphology of polypropylene. Polymer Testing, 2009, 28, 46-52.
41. Belyanskaya, L., Weigel, S., Hirsch, C., Tobler, U., Krug, H. F. and Wick, P. Effects of carbon nanotubes on primary neurons and glial cells. NeuroToxicology, 2009, 30, 702-711.
42. Lacerda, L., Bianco, A., Prato, M. and Kostarelos, K. Carbon nanotubes as nanomedicines: from toxicology to pharmacology. Adv. Drug Deliv. Rev, 2006, 58, 1460-1470.
43. Richardson-Burns, S. M., Hendricks, J. L., Foster, B., Povlich, L. K., Kim, D.-H. and Martin, D. C. Polymerization of the conducting polymer poly(3, 4-ethylenedioxythiophene) (PEDOT) around living neural cells. Biomaterials, 28, 2007, 1539-1552.
44. Guimard, N. K., Gomez, N. and Schmidt, C. E. Conducting polymers in biomedical engineering. Prog. Polym. Sci., 2007, 32 876-921.
45. Metodiewa, D. and Koska, C. Reactive oxygen species and reactive nitrogen species: relevance to cyto(neuro)toxic events and neurologic disorders. An overview. Neurotox. Res., 2000, 1, 197-233.
46. Koo, O. M., Rubinstein, I. and Onyuksel, H. Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomed. Nanotechnol. Biol., Med., 2005, 3, 193-212.
47. Kabanov, A. and Gendelman, H. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog. Polym. Sci., 2007, 32, 1054-1082.
48. Jahanshahi, M., Sanati, M., Minuchehr, Z., Hajizadeh, S. and Babaei, Z. Controlled fabrication of gelatin nanoparticles as a drug carrier. Nanotechnology and its Application. Am. Inst. Phy., 2007a, 929, 228.
49. Yu, S., Yao, P., Jiang, M. and Zhang, G. Nanogels prepared by self-assembly of oppositely charged globular proteins. Biopolymers, 2006, 83, 148-158.
50. Elzoghby, A. O., Samy, W. M. and Elgindy, N. A. Albumin-based nanoparticles as potential controlled release drug delivery systems. J. Controlled Release, 2012, 157, 168-182.
51. Lee, S. H., Heng, D., Ng, W. K., Chan, H. K. and Tan, R. B. Nano spray drying: a novel method for preparing protein nanoparticles for protein therapy. Int. J. Pharm., 2011, 403 192-200.
52. Kreuter, J. Nanoparticles in Colloidal drug delivery systems. J.K. Ed. Marcel Dekker: New York 1994, 219-342.
53. Verger, M. L.-L., Fluckiger, L., Kim, Y.-I., Hoffman, M. and Maincent, P. Preparation and characterization of nanoparticles containing an antihypertensive agent. Eur. J. Pharm. Biopharm., 1998, 46, 2 137-143.
54. Jahanshahi, M. and ISBN: Molecular Nanotechnology & Nanobiotechnology. Academic University (Mazandaran) publications, 2007.
55. Kreuter, J. Peroral administration of nanoparticles. Adv. Drug Del. Rev., 1991b, 7, 71-86.
56. Desai, M., Labhasetwar, V., Walter, E., Levy, R. and Amidon, G. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm. Res., 1997, 14, 1568-1573.
57. Zauner, W., Farrow, N. and Haines, A. In vitro uptake of polystyrene microspheres: effect of particles size, cell line and cell density. J. controlled release., 2001, 71, 39-51.
58. Redhead, H., Davis, S. and Illum, L. Drug delivery in poly (lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation. J. Control Release, 2001, 70, 353-363.
59. Dunne, M., Corrigan, O. and Ramtoola, Z. Influence of particle size and dissolution conditions on the degradation properties of polylactide-co-glycolide particles. Biomaterials, 2000, 21, 1659-1668.
60. Rahimnejad, M., Jahanshahi, M. and Najafpour, G. Production of biological nanoparticles from bovine serum albumin for drug delivery. Afr. J. Biotechnol., 5, 20 2006a, 1918-1923.
61. Rahimnejad, M., Jahanshahi, M., Najafpour, G. and Mehdinia, M. Fabrication of bovine serum albumin nanoparticles self-assembled coacervation method for drug delivery systems. J. Tech. Engine, 2006, 4, 26-34.
62. Muller, R. and Wallis, K. Surface modification of i.v. injectable biodegradable nanoparticles with poloxamer polymers and poloxamine 908. Int. J. Pharm., 1993, 89, 25-31.
63. Mohanraj, V. and Chen, Y. Nanoparticles-a review. Trop. J. Pharm. Res., 2006, 5, 561-573.
64. Jahanshahi, M., Williams, S., Lyddiatt, A. and Shojaosadati, S. J. IEE Nanobiotechnol., 2004, 151, 176.
65. Jahanshahi, M. Re-design of downstream processing techniques for nanoparticulate bioproducts. Iranian J. Biotechnol., 2004, 2, 10-12.
66. Aubert, D., Pichard, V., Durand, S., Moullier, P. and Ferry, N. Immune response and gene transfer. Hum. Gene Ther., 2003, 14, 473-481.
67. Lorens, J., Sousa, C., Bennett, M., Molineaux, S. and Payan, D. The use of retroviruses as pharmaceutical tools for target discovery and validation in the field of functional genomics. Curr. Opin. Biotechnol., 2001, 12, 613-621.
68. Harmin, T., Speiser, P. and Kreuter, J. A solid colloidal drug delivery system for the eye: encapsulation of pilocarpin in nanoparticles. J. Microencapsul., 1986, 33-12.
69. Breitenbach, M., Kamm, W., Hungere, K., Hund, H. and Kissel, T. Oral and nasal administration of tetanus toxoid loaded nanoparticles consisting of novel charged biodegradable polyesters for mucosal vaccination. Proc. Intern. Symp. Control. Release. Bioact. Mater., 1999, 26, 348-349.
70. Couvreur, P. and Puisieux, F. Nano and microparticles for the delivery of polypeptides and proteins. Adv. Drug Del. Rev., 1993, 10, 141-162.
71. Soppimath, K., Aminabhavi, T., Kulkarni, A. and Rudzinski, W. Biodegradable polymeric nanoparticles as drug delivery devices. J. controlled release, 2001, 7, 1-20.
72. Faraji, A. H. and Wipf, P. Nanoparticles in cellular drug delivery. Bioorg. Med. Chem., 2009, 17, 2950-2962.
73. Kreuter, J. and (Ed.), J. B. J. S. Encyclopedia of Pharma. Tech. Marcel Dekker, New York, 1994, 165-190.
74. Garcia-Fuentes, M., Torres, D. and Alonso, M. J. New surfacemodified lipid nanoparticles as delivery vehicles for salmon calcitonin, 2005, 296, 122-132.
75. Fonseca, M. J., Jagtenberg, J. C., Haisma, H. J. and Storm, G. Liposome-mediated targeting of enzymes to cancer cells for sitespecific activation of prodrugs: comparison with the corresponding antibody-enzyme conjugate. Pharm. Res., 2003, 20, 423-428.
76. Zhang, L. and Granick, S. How to stabilize phospholipid liposome (using nanoparticles). Nano Lett., 2006, 6, 694-698.
77. Torchilin, V. P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov., 2005, 4, 145-159.
78. Moghimi, S. M. and Szebeni, J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res., 2003, 42, 463-478.
79. Zhang, L., Gu, F., Chan, J., Wang, A., Langer, R. and Farokhzad, O. Nanoparticles in Medicine: Therapeutic Applications and Developments. Clin. Pharmacol. Ther., 2008, 83, 761-769.
80. Liversidge, G. G. and Cundy, K. C. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int. J. Pharm., 1995, 125, 91-97.
81. Shibahara, A., Hoshino, A., Hanaki, K., Suzuki, K. and Yamamoto, K. On the cyto-toxicity caused by quantum dots. Microbiol. Immunol., 2004, 48, 669-675.
82. Jahanshahi, M., Seresht, R. J. and Hajizadeh, S. Catalysts effects on the production of carbon nanotubes by an automatic arc discharge set up in solution. P hys. Status Solidi C, 2009, 6(10), 2174-2178.
83. Kagan, V. E., Tyurina, Y. Y., Tyurin, V. A., Konduru, N. V., Potapovich, A. I., Osipov, A. N., Kisin, E. R., Schwegler-Berry, D., Mercer, R., Castranova, V. and Shvedova, A. A. Direct and indirect effects of single walled carbon nanotubes on RAW 264.7 macrophages: role of iron. Toxicol. Lett., 2006, 165, 88.
84. Lee, C., MacKay, J., Frechet, J. and Szoka, F. Designing dendrimers for biological applications. Nat. Biotechnol., 2005, 23, 1517-1526.
85. Jahanshahi, M., Aghajani, H. and Ling, T. assembly and purification of nanostructure bioproducts: protein nanoparticle characterizations and non-stick exterior coating adsorbents. Int. J. Nanosci. Nanotech., 2005, 1, 9-19.
86. Soppimath, K., Aminabhavi, T., Kulkarni, A. and Rudzinski, W. Biodegradable polymeric nanoparticles as drug delivery devices. J. controlled release, 2001, 71-20.
87. Mohanraj, V. and Chen, Y. Nanoparticles-A Review. Trop. J. Pharm. Res., 2006, 5, 561-573.
88. Lockman, P. R., Mumper, R. J., Khan, M. A. and Allen, D. D. Nanoparticle Technology for Drug Delivery Across the Blood-Brain Barrier. Drug Develop. Industrial Pharm., 2002, 28, 1-13.
89. Mehravar, R., Jahanshahi, M. and Saghatoleslami, N. Fabrication and evaluation of human serum albumin (hsa) nanoparticles for drug delivery application. Intl J. Nanosci., 2009, 8, 319-322.
90. Ferrer, M. L., Duchowicz, R., Carrasco, B., Torre, J. G. d. l. and Acuña, A. U. The conformation of serum albumin in solution: a combined phosphorescence depolarization-hydrodynamic modeling study. Biophys. J., 2001, 80, 2422-2430.
91. Dror, Y., Cohen, Y. and Yerushalmi-Rozen, R. Structure of gumArabic in aqueous solutions. J. Polym. Sci. Part B: Polym. Phys., 44, 2006, 3265-3271.
92. Roque, A. C. A., Bicho, A., Iris, L. Batalha, A. S. Cardoso and Hussain, A. Biocompatible and bioactive gumArabic coated iron oxide magnetic nanoparticles. J. Biotechnol., 2009, 144, 313-320.
93. Nishi, K. K. and Jayakrishnan, A. Self-gelling primaquinegumArabic conjugate: an injectable controlled delivery system for primaquine. Biomacromology, 2007, 8, 84-90.
94. Chang, C.-P., Leung, T.-K., Lin, S.-M. and Hsu, C.-C. Release properties on gelatin-gumArabic microcapsules containing camphor oil with added polystyrene. Colloid Surf. B: Biointerf., 2006, 50, 136-140.
95. Babaei, Z., Jahanshahi, M. and Sanati, M. H. Fabrication and evaluation of gelatin nanoparticles for delivering of anti-cancer drug. Intl J. Nanosci. Nanotechnol., 2008, 4, 23-29.
96. Ofokansi, K., Winter, G., Fricker, G. and Coester, C. Matrix-loaded biodegradable gelatinnanoparticles as new approach to improve drug loading and delivery. Eur. J. Pharm. Biopharm., 2010, 76, 1-9.
97. Bourquin, C., Anz, D., Zwiorek, K., Lanz, A. L., Fuchs, S., Weigel, S., Wurzenberger, C., Borch, P. v. d., Golic, M., Moder, S., Winter, G., Coester, C. and Endres, S. Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity. J. Immunol., 2008, 181, 2990-2998.
98. Zwiorek, K., Bourquin, C., Battiany, J., Winter, G., Endres, S., Hartmann, G. and Coester, C. Delivery by cationic gelatinnanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides. Pharm. Res., 2008, 25, 551-562.
99. Weber, C., Coester, C., Kreuter, J. and Langer, K. Desolvation process and surface characterization of protein nanoparticles. Int. J. Pharm., 2000, 194, 91-102.
100. Silva, G. A. Neuroscience nanotechnology: progress, opportunities and challenges. Nat. Rev. Neurosci., 2006, 7, 65-74.
101. Popescu, G. Chapter 5 Quantitative Phase Imaging of Nanoscale Cell Structure and Dynamics. Methods Cell Biol., 2008, 90, 87-115.
102. Irache, J. M., Esparza, I., Gamazo, C., Agüeros, M. and Espuelas, S. Nanomedicine: Novel approaches in human and veterinary therapeutics. Veterinary Parasitol., 2011, 180, 47-71.
103. Jones, S., Robbins, J. and Brown, D. A. Neurotransmitter modulation of calcium channels is dependent on the charge carrier used in the recording of currents. Neurosci. Lett., 1992, 145, 153-156.
104. Boriani, G., Regoli, F., Saporito, D., Martignani, C., Toselli, T., Biffi, M., Francolini, G., Diemberger, I., Bacchi, L., Rapezzi, C., Ferrari, R. and Branzia, A. Neurohormones and inflammatory mediators in patients with heart failure undergoing cardiac resynchronization therapy: Time courses and prediction of response. Peptides, 2006, 27, 1776-1786.
105. Eric Herlenius and Lagercrantz, H. Neurotransmitters and neuromodulators during early human development. Early Hum. Develop., 65, 2001, 21-37.
106. Louboutin, J.-P., Agrawal, L., Reyes, B. A. S., Bockstaele, E. J. V. and Strayer, D. S. Gene delivery of antioxidant enzymes inhibits HIV-1 gp120-induced expression of caspases. Neuroscience, In Press 2012).
107. Pivovarov, A. S. Regulation of neuron cholinoreceptor plasticity of Helix lucorum by secondmessengers and opioids. Comparative Biochemistry and Physiology Part C: Pharmacol. Toxicol. Endocrinol., 1995, 110, 229-240.
108. Reithmeier, R. A. F. Mammalian exchangers and co-transporters. Curr. Opin. Cell Biol., 1994, 6, 583-594.
109. Raiteri, L., Raiteri, M. and Bonanno, G. Coexistence and function of different neurotransmitter transporters in the plasma membrane of CNS neurons. Prog. Neurobiol., 2002, 68, 287-309.
110. Chung, S.-H. and Kuyucak, S. Recent advances in ion channel research. Biochimica et Biophysica Acta (BBA)-Biomembr., 2002, 1565, 267-286.
111. Magnin, T., Fiez-Vandal, C., Potier, N., Coquard, A., Leray, I., Steffan, T., Logez, C., Alkhalfioui, F., Pattus, F. and Wagner, R. A novel, generic and effective method for the rapid purification of G protein-coupled receptors. Protein Expr. Purif., 2009, 64, 1-7.
112. Price, D. D., Barrell, J. J. and Rainville, P. Integrating experientialphenomenological methods and neuroscience to study neural mechanisms of pain and consciousness. Conscious Cogn., 2002, 11, 593-608.
113. Mutez, E., Duhamel, A., Defebvre, L., Bordet, R., Destée, A. and Kreisler, A. Lipid-lowering drugs are associated with delayed onset and slower course of Parkinson's disease. Pharmacol. Res., 2009 60, 41-45.
114. Heinrich, M. and Teoh, H. L. Galanthamine from snowdrop-the development of a modern drug against Alzheimer's disease from local Caucasian knowledge. J. Ethnopharmacol., 2004, 92, 147-162.
115. Freeman, C. Psychological and drug therapies for post-traumatic stress disorder. Psychiatry, 2006, 5, 231-237.
116. Robbins, T., Cardinal, R. N., DiCiano, P., Halligan, P. W., Hellemans, K., Lee, J. and Everitt, B. J. Chapter 3-Neuroscience of Drugs and Addiction. Drugs Future-Brain Sci, Addiction and Soc., 2007, 11-87.
117. Serwer, L. P. and James, C. D. Challenges in drug delivery to tumors of the central nervous system: An overview of pharmacological and surgical considerations. Adv. Drug Deliv. Rev., 2012, 64, 590-597.
118. Xi, W., Tian, M. and Zhang, H. Molecularimaging in neuroscience research with small-animal PET in rodents. Neurosci. Res., 2011, 70, 133-143.
119. Ahmed, B., Driver, J., Friston, K., Matus, A., Morris, R. and Rolls, E. Chapter 11-Advanced neuroscience technologies. Cognitive Systems-Information Proc. Meets Brain Sci., 2006, 263-282, XIIIXIV.
120. Amadoa, S., Simões, M. J., Silva, P. A. S. A. d., Luís, A. L., Shirosaki, Y., Lopes, M. A., Santos, J. D., Fregnan, F., Gambarotta, G., Raimondo, S., Fornaro, M., Veloso, A. P., Varejão, A. S. P., Maurício, A. C. and Geuna, S. Use of hybrid chitosan membranes and N1E-115 cells for promoting nerve regeneration in an axonotmesis rat model. Biomaterials, 2008, 29, 33, 4409-4419.
121. Czuczwar, S. J. Inflammation{pipe} Neurodegeneration, Neuroprotection and Inflammation in the Brain. Encyclopedia Basic Epilepsy Res., 2009, 600-604. http://books.google.com/books?id=fPiWNqym TkYC&pg=PT1654&lpg=PT1654&dq=Czuczwar,+S.+J.+Inflamm ation{pipe}+Neurodegeneration,+Neuroprotection+and+Inflammation+in +the+Brain&source=bl&ots=_axJyylcTA&sig=HxSqR1wy2enH60 Le6Lpdfp3HWNQ&hl=en&sa=X&ei=tjqnUNOhEOqj0QX38ICY CA&ved=0CDMQ6AEwAA
122. Chen, Y. and Liu, L. Modern methods for delivery of drugs across the blood-brain barrier. Adv. Drug Deliv. Rev., 2012, 64, 640-665.
123. Pardridge, W. M. and Boado, R. J. Chapter eleven-Reengineering Biopharmaceuticals for TargetedDeliveryAcross the Blood-Brain Barrier. Methods Enzymol., 2012, 503, 269-292.
124. Bawa, R. and Wei, C. Recent Advances in Basic and Clinical Nanomedicine. Med. Clin. North Am., 2007, 91, 805-843.
125. Birrenbach, G. and Speiser, P. P. Polymerized micelles and their use as adjuvants in immunology. J. Pharm. Sci., 1976, 65, 1763-1766.
126. Zolle, I., Hosain, F., Rhodes, B. A. and Wagner, H. N. Human serum albumin millimicrospheres for studies of reticuloendothelial system. Nucl. Med., 111970), 379-380.
127. Ringsdorf, H. Structure and properties of pharmacologically active polymers. J. Polymer Sci: Polymer Symposia, 1975, 51, 135-153.
128. Duncan, R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer, 2006, 6, 688-701.
129. Kreuter, J. Nanoparticles and nanocapsules: New dosage forms in the nanometer size range. Pharm. Acta Helv., 1978, 53, 33-39.
130. Kreuter, J. Drug targeting with nanoparticles. Eur. J. Drug Metab. Pharmacokinet., 1994, 19, 253-256.
131. Kreuter, J. Nanoparticles as drug delivery systems. Encyclopedia Nanosci. Nanotechnol., 2004, 7, 161-180.
132. Farokhzad, O. C. and Langer, R. Impact of Nanotechnology on Drug Delivery. ACS Nano, 2009, 3, 16-20.
133. Ferrari, M. Cancer Nanotechnology: Opportunities and Challenges. Nat. Rev. Cancer, 2005, 5, 161-171.
134. Labhasetwar, V. Nanotechnology for drug and gene therapy: the importance of understanding molecular mechanisms of delivery. Curr. Opin. Biotechnol., 2005, 16, 674-680.
135. Panyam, J., Labhasetwar, V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev., 2003, 12, 329-347.
136. Emerich, D. F. and Thanos, C. G. The pinpoint promise of nanoparticle-baseddrug delivery and molecular diagnosis. Biomol. Eng., 2006, 23, 171-184.
137. Moghimi, S. M. Modulation of lymphatic distribution of subcutaneously injected poloxamer 407-coated nanospheres: the effect of the ethylene oxide chain configuration. FEBS Lett., 2003, 540, 241-244.
138. Cherukuri, P., Bachilo, S.M., Litovsky, S.H., Weisman, R.B. Nearinfrared fluorescence microscopy of single-walled carbon nanotunes in phagocytic cells. J. Am. Chem. Soc., 2004, 126, 15638-15639.
139. Singh, R., Pantarotto, D., Lacerdo, L., Pastorin, G., Klumpp, C., Prato, M., Bianco, A. and Kostarelos, K. Tissue biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracers. PNAS, 2006, 103, 3357-3362.
140. Moghimi, S. M. and Hunter, A. C. Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups. Pharm. Res., 2001, 18, 1-8.
141. Moghimi, S. M., Szebeni, J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res., 2003, 42, 463-478.
142. Moghimi, S. M., Hunter, A. C. and Murray, J. C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev., 2003, 53, 283-318.
143. Moghimi, M., Hunter, A. C. and Murray, J. C. Nanomedicine: current status and future prospects. FASEB, 2005, 19, 311-330.
144. Nel, A., Xia, T., Madler, L. and Li, N. Tox potential of materials at the nanolevel. Science, 2006, 311, 622-627.
145. Akerman, M. E., Chan, W. C., Laakkonen, P., Bhatia, S. N. and Ruoslahti, E. Nanocrystal targeting in vivo. Proc. Natl. Acad. Sci. USA, 2002, 99, 12617-12621.
146. Ballou, B., Lagerholm, B. C., Ernst, L. A., Bruchez, M. P. and Waggoner, A. S. Noninvasive imaging of quantum dots in mice. Bioconjug. Chem., 2004, 15, 79-86.
147. Vasir, J. K. and Labhasetwar, V. Targeted drug delivery in cancer therapy. Technol. Cancer Res. Treat., 2005, 4, 363-374.
148. Moghimi, S. M. and Bonnemain, B. Subcutaneous and intravenous delivery of diagnostic agents to the lymphatic system: applications in lymphoscintigraphy and indirect lymphography. Adv. Drug Deliv. Rev., 1999, 37, 295-312.
149. Winter, P. M., Caruthers, S. D., Kassner, A., Harris, T. D., Chinen, L. K., Allen, J. S., Lacy, E. K., Zhang, H. Y., Robertson, J. D. and Wickline, S. A. Molecular imaging of angiogenesis in nascent vx-2 rabbit tumours using a novel alpha(v)beta(3)-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res., 2003, 63, 5838-5843.
150. Kim, S., Lim, Y. T., Soltesz, E. G., De Grand, A. M., Lee, J., Nakayama, A., Parker, J. A., Mihaljevic, T., Laurence, R. G. and Dor, D. M. Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat. Biotechnol., 2004, 22, 93-97.
151. Harisinghani, M. G., Barentsz, J., Hahn, P. F., Deserno, W. M., Tabatabaei, S., Hulsbergen, v. d. K. C. H., de la Rosette, J. and Weissleder, R. Noninvasive detection of clinically occult lymphnode metastases in prostate cancer. N. Engl. J. Med., 2003, 348, 2491-2499.
152. Ai, H., Meng, H., Ichinose, I., Jone, S. A., Mills, D. K., Lvov, Y. M. and Qiao, X. Biocompatibility of layer-by-layer selfassembled nanofilm on silicone rubber for neurons. J. Neurosci. Methods, 2003, 128, 1-8.
153. Kim, D. H., Abidian, M. and Martin, D. C. Conducting polymers grown in hydrogel scaffolds coated on neural prosthetic devices. J. Biomed. Mater. Res. A, 2004, 71, 577-585.
154. Moxon, K., Kalkhoran, N., Markert, M., Sambito, M., McKenzie, J. and Webster, J. Nanostructured surface modification of ceramic-based microelectrodes to enhance biocompatibility for a direct brain-machine interface. IEEE Trans. Biomed. Eng., 2004, 51, 881-889.
155. Vu, T., Chowdhury, S., Muni, N., Qian, H., Standaert, R. and Pepperberg, D. Activation of membrane receptors by a neurotransmitter conjugate designed for surface attachment. Biomaterials, 2005, 26, 1895-1903.
156. Saifuddin, U., Vu, T. Q., Reza, M., Qian, H., Pepperberg, D. R. and Desai, T. A. Assembly and characterization of biofunctional neurotransmitter-immobilized surfaces for interaction with postsynaptic membrane receptors. J. Biomed. Mater. Res. A, 2003, 66, 184-191.
157. Dahan, M., Lévi, S., Luccardini, C., Rostaing, P., Riveau, B. and Triller, A. Diffusion dynamics of glycine receptors revealed by single-quantum dot tracking. Science, 2003, 302, 442-445.
158. Howarth, M., Takao, K., Hayashi, Y. and Ting, A. Y. Targeting quantum dots to surface proteins in living cells with biotin ligase. Proc. Natl. Acad. Sci. USA, 2005, 1027583-7588.
159. Pathak, S., Cao, E., Davidson, M. C., Jin, S. and Silva, G. A. Quantum Dot Applications to Neuroscience: New Tools for Probing Neurons and Glia. J. Neurosci., 2006, 26, 1893-1895.
160. Luksch, H., Khanbabaie, R. and Wessel, R. Synaptic dynamics mediate sensitivity to motion independent of stimulus details. Nat. Neurosci., 2004, 7, 380-388.
161. Khanbabaie, R., Nesse, W. H., Longtin, A. and Maler, L. Kinetics of Fast Short-Term Depression Are Matched to Spike Train Statistics to Reduce Noise. J. Neurophysiol., 2010, 103, 3337-3348.
162. Kasthuri, N. and Lichtman, J. The role of neuronal identity in synaptic competition. Nature, 2003, 424, 426-430.
163. Stevens, C. Neurotransmitter release at central synapses. Neuron, 2003, 40, 381-388.
164. Li, Z. and Sheng, M. Some Assembly Required: the development of neuronal synapses. Nat. Rev. Mol. Cell Biol., 2003, 11, 833-841.
165. Say, R., Keçili, R., Biçen, Ö., Şişman, F. Y., Hür, D., Denizli, A. and Ersöz, A. A novel nanoprotein particle synthesis: Nanolipase. Proc. Biochemistry, 2011, 46, 1688-1692.
166. Bellamkonda, R., Ranieri, J. and Aebischer, P. Laminin oligopeptide derivatized agarose gels allow three-dimensional neurite extension in vitro. J. Neurosci. Res., 1995, 41, 4, 501-509.
167. Frade, J., Bovolenta, P. and Rodríguez-Tébar, A. Neurotrophins and other growth factors in the generation of retinal neurons. Microsc. Res. Tech., 1999, 45(4-5), 243-251.
168. Freire, E., Gomes, F., Jotha-Mattos, T., Neto, V., Silva, F. F. and Coelho-Sampaio, T. Sialic acid residues on astrocytes regulate neuritogenesis by controlling the assembly of laminin matrices. J. Cell Sci., 2004, 15, 117(Pt 18), 4067-4076.
169. Yurchenco, P., Cheng, Y. and Colognato, H. Laminin forms an independent network in basement membranes. J. Cell Biol., 117, 1992, 1119-1133.
170. Gnanavel, B. K. and Fernando, A. A. G. Introduction to Nannoengineering and its application in to neuroscience. Proceedings of the ASME 2011 International Mechanical Engineering Congress & Exposition IMECE2011(November 11-17 2011).
171. Carver, L. and Schnitzer, J. Caveolae: mining little caves for new cancer targets. Nat Rev Cancer, 2003, 3, 571-581.
172. Owens, r. D. and Peppas, N. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm., 2006, 307, 93-102.
173. Cornford, E. and Cornford, M. New systems for delivery ofdrugs to the brain in neurological disease. Lancet Neurol, 2002, 1, 306-315.
174. Roney, C., Kulkarni, P., Arora, V., Antich, P., Bonte, F., Wu, A., Mallikarjuana, N. N., Manohar, S., Liang, H.-F., Kulkarni, A. R., Sung, H.-W., Sairam, M. and Aminabhavi, T. M. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. J. Controlled Release, 2005, 108, 193-214.
175. Schnyder, A., Krahenbuhl, S., Drewe, J. and Huwyler, J. Targeting of daunomycin using biotinylated immunoliposomes: pharmacokinetics, tissue distribution and in vitro pharmacological effects. J. Drug Target., 2005, 13, 325-335.
176. Arifin, D. R. and Palmer, A. F. Polymersome encapsulated hemoglobin: a novel type of oxygen carrier. Biomacromolecules, 2005, 62, 172-2181.
177. Dutta, T., Agashe, H., Garg, M., Balakrishnan, P., Kabra, M. and Jain, N. Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro. J. Drug Target, 2007, 15, 89-98.
178. Morgan, M. T., Nakanishi, Y., Kroll, D. J., Griset, A. P., Carnahan, M. A., Wathier, M., Oberlies, N. H., Manikumar, G., Wani, M. C. and Grinstaff, M. W. Dendrimer-encapsulated camptothecins: increased solubility, cellular uptake, and cellular retention affords enhanced anticancer activity in vitro. Cancer Res., 2006, 66, 11913-11921.
179. Xie, Y. L., Lu, W. and Jiang, X. G. Improvement of cationic albumin conjugated pegylated nanoparticles holding NC-1900, a vasopressin fragment analog, in memory deficits induced by scopolamine in mice. Behav. Brain Res., 2006, 173, 76-84.
180. Wosikowski, K., Biedermann, E., Rattel, B., Breiter, N., Jank, P., Löser, R., Jansen, G. and Peters, G. In vitro and in vivo antitumor activity of methotrexate conjugated to human serum albumin in human cancer cells. Clin. Cancer Res., 2003, 9, 1917-1926.
181. Hyung Park, J., Kwon, S., Lee, M., Chung, H., Kim, J., Kim, Y., Park, R., Kim, I., Bong Seo, S., Kwon, I. and Young Jeong, S. Selfassembled nanoparticles based on glycol chitosan bearing hydrophobic moieties as carriers for doxorubicin: in vivo biodistribution and anti-tumor activity. Biomaterials, 2006, 27, 119-126.
182. Jordan, A., Scholz, R., Maier-Hauff, K., van Landeghem, F., Waldoefner, N., Teichgraeber, U., Pinkernelle, J., Bruhn, H., Neumann, F., Thiesen, B., von Deimling, A. and Felix, R. The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma. J. Neurooncol., 2006, 78, 7-14.
183. Jurgons, R., Seliger, C., Hilpert, A., Trahms, L., Odenbach, S. and Alexiou, C. Drug loaded magnetic nanoparticles for cancer therapy. J. Phys. Condens. Matter., 2006, 18, S2893-S2902.
184. Roy, I., Ohulchanskyy, T., Pudavar, H., Bergey, E., Oseroff, A., Morgan, J., Dougherty, T and Prasad, P. Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic therapy. J. Am. Chem. Soc., 2003, 125, 7860-7865.
185. Qisheng, H., Jun, L., Li-Qiong, W., Yingbing, J., Timothy, N. L. and Erica, F. A new class of silica cross-linked micellar core-shell nanoparticles. J. Am. Chem. Soc., 2006, 128, 6447-6453.
186. Oyewumi, M., Yokel, R., Jay, M., Coakley, T. and Mumper, R. Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumorbearing mice. J. Control Release, 95, 2004, 613-626.
187. Chithrani, B. D. and Chan, W. C. W. Elucidating the Mechanism of Cellular Uptake and Removal of Protein-Coated Gold Nanoparticles of Different Sizes and Shapes. Nano Lett., 2007, 7, 1542-1550.
188. Chithrani, B. D., Ghazani, A. A. and Chan, W. C. W. Determining the Size and Shape Dependence of Gold Nanoparticle Uptake into Mammalian Cells. Nano Lett., 2006, 6, 662.
189. Chenevier, P., Veyret, B., Roux, D. and Henry-Toulmé, N. Interaction of cationic colloids at the surface of J774 cells: a kinetic analysis. Biophys. J., 2000, 79, 1298-1309.
190. Miller, C., Bondurant, B., McLean, S., McGovern, K. and O'Brien, D. Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. Biochemistry, 1998, 37, 12875-12883.
191. Alyaudtin, R., Reichel, A., Löbenberg, R., Ramge, P., Kreuter, J. and Begley, D. Interaction of poly(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro. J. Drug Target., 2001, 9, 209-221.
192. Jaulin, N., Appel, M., Passirani, C., Barratt, G. and Labarre, D. Reduction of the uptake by a macrophagic cell line of nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate). J. Drug Target, 2000, 8, 165-172.
193. Nam, H. Y., Kwon, S. M., Chung, H., Lee, S.-Y., Kwon, S.-H., Jeon, H., Kim, Y., Park, J. H., Kim, J., Her, S., Oh, Y.-K., Kwon, I. C., Kim, K. and Jeong, S. Y. Cellular uptakemechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles. J. Controlled Release, 2009, 135, 259-267.
194. Gupta, A. K. and Gupta, M. Cytotoxicity suppression and cellular uptake enhancement of surface modified magnetic nanoparticles. Biomaterials, 2005, 26, 1565-1573.
195. Chouly, C., Pouliquen, D., Lucet, I., Jeune, J. J. and Jallet, P. Development of superparamagentic nanoparticles for MRIeffect of particle size, charge and surface nature on biodistribution. J. Microencapsul., 1996, 32, 45-255.
196. Moghimi, S. M., Hunter, A. C. and Murray, J. C. Long circulating and target specific nanoparticlestheory to practise. Pharm. Rev., 2001, 53, 283-318.
197. Stolnik, S., Illum, L. and Davis, S. S. Long circulating microparticulate drug carriers. Adv. Drug Del. Rev., 1995, 16, 195-214.
198. Weissleder, R., Kelly, K., Sun, E. Y., Shtatland, T. and Josephson, L. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat. Biotechnol., 2005, 23, 1418-1423.
199. Jabari Seresht, R. and Jahanshahi, M. Parametric study on the synthesis of single wall carbon nanotube by gas arc-discharge method with multiple linear regressions and artificial neural network. Intl J. Nanosci., 2009, 8, 243-249.
200. Tran, P. A., Zhang, L. and Webster, T. J. Carbon nanofibers and carbon nanotubes in regenerative medicine. Adv. Drug Del. Rev., 2009, 61, 1097-1114.
201. Kroto, H. W., Heath, J. R., O'Brien, S. C., Curl, R. F. and Smalley, R. E. C60: buckminsterfullerene. Nature, 1985, 318, 162-163.
202. Silva, G. A., Czeisler, C., Niece, K. L., Beniash, E., Harrington, D. A., Kessler, J. A. and Stupp, S. I. Selective differentiation of neural progenitor cells by high-epitope density nanofibers. Science, 2004, 303, 1352-1355.
203. Dugan, L., Lovett, E., Quick, K., Lotharius, J., Lin, T. and O'Malley, K. Fullerene-based antioxidants and neurodegenerative disorders. Parkinsonism Relat Disord., 2001, 7, 243-246.
204. Jin, H., Chen, W., Tang, X., Chiang, L., Yang, C., Schloss, J. and Wu, J. Polyhydroxylated C(60), fullerenols, as glutamate receptor antagonists and neuroprotective agents. J. Neurosci. Res., 2000, 62, 600-607
205. Dugan, L., Lovett, E., Quick, K., Lotharius, J., Lin, T. and O'Malley, K. Fullerene-based antioxidants and neurodegenerative disorders. Parkinsonism Relat. Disord., 2001, 7, 243-246.
206. Dugan, L. L., Gabrielsen, J. K., Yu, S. P., Lin, T. S. and Choi, D. W. Buckminsterfullerenol free radical scavengers reduce excitotoxic and apoptotic death of cultured cortical neurons. Neurobiol. Dis., 1996, 3, 129-135.
207. Schroeder, U., Sommerfeld, P., Ulrich, S. and Sabel, B. A. Nanoparticle technology for delivery of drugs across the bloodbrain barrier. J. Pharm. Sci., 1998, 87, 1305-1307.
208. Kreuter, J., Ramge, P., Petrov, V., Hamm, S., Gelperina, S., Engelhardt, B., Alyautdin, R., von Briesen, H. and Begley, D. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm. Res., 2003, 20, 409-416.
209. Lockman, P. R., Mumper, R. J., Khan, M. A. and Allen, D. D. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev. Ind. Pharm., 2002, 28, 1-13.
210. Vinogradov, S. V., Batrakova, E. V. and Kabanov, A. V. Nanogels for oligonucleotide delivery to the brain. Bioconjug. Chem., 2004, 15, 50-60.
211. Koziara, J. M., Lockman, P. R., Allen, D. D. and Mumper, R. J. In situ blood-brain barrier transport of nanoparticles. Pharm. Res., 2003, 20, 1772-1778.
212. Olbrich, C., Gessner, A., Kayser, O. and Muller, R. H. Lipid-drugconjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. J. Drug Target, 2002, 10, 387-396.
213. Miller, D. S. Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol. Sci., 2010, 31, 246-254.
214. Mayeux, R. Epidemiology of neurodegeneration. Annu. Rev. Neurosci, 2003, 26, 81-104.
215. Au, W. L., Adams, J. R., Troiano, A. and Stoessl, A. J. Neuroimaging in Parkinson's disease. J. Neural. Transm. Suppl., 2006, 241-248.
216. Boska, M. D., Mosley, R. L., Nawab, M., Nelson, J. A., Zelivyanskaya, M., Poluektova, L., Ubertia, M., Dou, H., Lewis, T. B. and Gendelman, H. E. Advances in neuroimaging for HIV-1 associated neurological dysfunction: clues to the diagnosis, pathogenesis and therapeutic monitoring. Curr. HIV Res., 2004, 2, 61-78.
217. Popescu, G. Quantitative Phase Imaging of Cells and Tissues. McGraw-Hill, 2011.
218. Dhib-Jalbut, S., Arnold, D. L., Cleveland, D. W., Fisher, M., Friedlander, R. M., Mouradian, M. M., Serge, P., Trapp, B. D., Wyss-Coray, T. and Yong, V. W. Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases. J. Neuroimmunol., 2006, 176, 198-215.
219. Bocti, C., Rockel, C. and Roy, P. Topographical patterns of lobar atrophy in frontotemporal dementia and Alzheimer's disease. Dement. Geriatr. Cogn. Disord., 2006, 21, 364-372.
220. Burn, D. and O'Brien, J. Use of functional imaging inParkinsonism and dementia. Mov. Disord., 2003, 18(Suppl. 6), S88-95.
221. Khachaturian, Z. Diagnosis of Alzheimer's disease: twodecades of progress. J. Alzheimers Dis., 2006, 9, 409-415.
222. Silverman, D. and Alavi, A. PET imaging in the assessment ofnormal and impaired cognitive function. Radiol. Clin. North Am., 2005, 43, 67-77.
223. Walker, Z. and Walker, R. Imaging in neurodegenerativedisorders: recent studies. Curr. Opin. Psychiatry, 2005, 18, 640-646.
224. Silva, G. Nanotechnology approaches for the regeneration and neuroprotection of the central nervous system. Surg. Neurol., 2005, 63, 301-306.
225. Shaw, L., Korecka, M., Clark, C., Lee, V. and Trojanowski, J. Biomarkers of neurodegenertion for diagnosis and monitoring therapeutics. Nat. Rev. Drug Discov., 2007, 6, 295-303.
226. Angeloni, N. L., Bond, C. W., Tang, Y., Harrington, D. A., Zhang, S., Stupp, S. I., McKenna, K. E. and Podlasek, C. A. Regeneration of the cavernous nerve by Sonic hedgehog using aligned peptide amphiphile nanofibers. Biomaterials, 2011, 32, 1091-1101.
227. Patel, T., Zhou, J., Piepmeier, J. M. and Saltzman, W. M. Polymeric nanoparticles for drug delivery to the central nervous system. Adv. Drug Deliv. Rev., 2012, 64, 701-705.
228. Gupta, A. S. Nanomedicine approaches in vascular disease: a review. Nanomed. Nanotechnol. Biol. Med., 2011, 7, 763-779.
229. Schmidt, J., Metselaar, J., Wauben, M., Toyka, K., Storm, G. and Gold, R. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain, 2003, 126, 1895-1904.
230. Rousseau, V., Denizot, B., Jeune, J. J. L. and Jallet, P. Early detection of liposome brain localization in rat experimental allergic encephalomyelitis. Exp. Brain Res., 1999, 125, 255-264.
231. Alyaudtin, R. N., Reichel, A., Löbenberg, R., Ramge, P., Kreuter, J. and Begley, D. J. Interaction of Poly(butylcyanoacrylate) Nanoparticles with the Blood-Brain Barrier in vivo and in vitro. J Drug Target, 2001, 9, 209-221.
232. Miller, D. W. and Kabanov, A. V. Potential applications of polymers in the delivery of drugs to the central nervous system. Colloids and Surfaces B: Biointerfaces, 1999, 16, 321-330.
233. Kreuter, J. Influence of the surface properties on nanoparticlemediated transport of drugs to the brain. J. Nanosci. Nanotechnol., 2004, 4, 484-488.
234. Kreuter, J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev., 2001, 47, 65-81.
235. Jacobs, C., Kayser, O. and Muller, R. H. Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. Int. J. Pharm., 2000, 196, 161-164.
236. Rabinow, B. E. Nanosuspensions in drug delivery. Nat. Rev. Drug Discov., 2004, 3, 785-796.
237. Kwon, G. S. Polymeric micelles for delivery of poorly watersoluble compounds. Crit. Rev. Ther. Drug Carrier Syst., 2003, 20, 357-403.
238. Kabanov, A., Chekhonin, V., Alakhov, V., Batrakova, E., Lebedev, A., Melik-Nubarov, N., Arzhakov, S., Levashov, A., Morozov, G. and Severin, E. The neuroleptic activity of haloperidol increases after its solubilization in surfactant micelles. Micelles as microcontainers for drug targeting. FEBS Lett., 1989, 258, 343-345.
239. Oliveira, J. M., Salgado, A. J., Sousa, N., Mano, J. F. and Reis, R. L. Dendrimers and derivatives as a potential therapeutic tool in regenerative medicine strategies-A review. Prog. Polymer Sci, 2010, 35, 1163-1194.
240. Yiyun, C. and Tongwen, X. Dendrimers as Potential Drug Carriers. Part I. Solubilization of Non-Steroidal Anti-Inflammatory Drugs in the Presence of Polyamidoamine Dendrimers. Eur. J. Med. Chem., 40, 2005, 1188-1192.
241. Emerich, D. F. and Thanos, C. Nanotechnology and medicine: the here and now and future prospects. Expert Opin. Biol. Ther., 2003, 3, 655-663.
242. Clark, H., Kopelman, R., Tjalkens, R. and Philbert, M. A. Optical nanosensors for chemical analysis inside single living cells. 2. Sensors for pH and calcium and the intracellular application of PEBBLE sensors. Anal. Chem., 1999, 71, 4837-4843.
243. Sumner, J. P., Aylott, J. W., Monson, E. and Kopelman, R. A fluorescent PEBBLE nanosensor for intracellular free zinc. Analyst, 2002, 127, 11-16.
244. Wunderbaldinger, P., Josephson, L., Weissleder, R. and 13 Tat peptide directs enhanced clearance and hepatic permeability of magnetic nanoparticles. Bioconjug. Chem., 2002, 13, 264-268.
245. Lanza, G. M., Wallace, K. D., Scott, M. J., Cacheris, W. P., Abendschein, D. R., Christy, D. H., Sharkey, A. M., Miller, J. G., Gaffney, P. J. and Wickline, S. A. A novel site-targeted ultrasonic contrast agent with broad biomedical application. Circulation, 1996, 94, 3334-3340.